Prime Editing Enters the Clinic: First Human Results and What They Mean

The Day Prime Editing Left the Lab

On a spring day in May 2025, a patient at a medical center received an infusion of their own bone marrow stem cells — cells that had been removed, corrected at a single point in their DNA, and returned to their body. This was not the first gene therapy. It was not the first time CRISPR technology had been used in a person. But it was a genuine first of its kind: the first time prime editing — the most precise and versatile form of gene editing ever devised — had been tested in a human being.

The therapy was called PM359, developed by Prime Medicine, a Cambridge, Massachusetts-based company founded to commercialize the technology. The patient had chronic granulomatous disease (CGD), a rare and often devastating immune disorder. And the results, published months later in the New England Journal of Medicine, were not just good. They exceeded what anyone had reasonably hoped for.

To understand why this matters, you need to appreciate how far the field traveled to reach this moment. In 2012, Jennifer Doudna and Emmanuelle Charpentier published the foundational work on CRISPR-Cas9 as a programmable gene editing tool. In 2016, David Liu at the Broad Institute of MIT and Harvard introduced base editing, which could change individual DNA letters without cutting the double helix. And in October 2019, Liu's lab published a paper in Nature describing prime editing — a technology that could find a specific DNA sequence and rewrite it, much like the find-and-replace function in a word processor, without making a double-strand break.

Six years from publication to a patient. In the world of gene therapy, that pace is extraordinary.

This article will walk you through the science of prime editing, the details of the first clinical results, why Prime Medicine made the surprising decision to wind down its CGD program despite spectacular data, and what all of this means for the future of genetic medicine.

What Is Prime Editing? A Quick Refresher

If you have read our comprehensive guide to prime editing, you know the details. Here is the condensed version.

The "Search-and-Replace" for DNA

Prime editing is a gene editing technology that can find a specific DNA sequence in the genome and rewrite it — without cutting both strands of the DNA helix. Think of it this way: if CRISPR-Cas9 is a pair of molecular scissors, and base editing is a pencil eraser that can change one letter at a time, prime editing is the find-and-replace function in a word processor. It searches for the exact passage you want to change, highlights it, and types in the correction.

How It Differs from CRISPR-Cas9 and Base Editing

CRISPR-Cas9 works by making a double-strand break (DSB) in DNA at a target location. The cell's repair machinery then patches the break, and researchers exploit this process to disrupt genes or insert new sequences. The problem is that double-strand breaks are inherently dangerous. The cell's repair processes are imprecise — they can introduce unintended insertions, deletions, or even large chromosomal rearrangements. In a therapeutic context, these off-target effects are a serious safety concern.

Base editing, also invented by David Liu, avoids double-strand breaks by chemically converting one DNA base to another at a target site. Cytosine base editors (CBEs) convert C-to-T, and adenine base editors (ABEs) convert A-to-G. This is elegant and efficient, but limited: base editors can only make 4 of the 12 possible single-letter changes, and they cannot perform insertions or deletions. They also sometimes edit neighboring bases that happen to be in the editing window — so-called bystander edits.

Prime editing avoids both problems. It makes no double-strand break, and it can perform all 12 types of point mutations, plus small insertions (up to ~50 base pairs) and deletions (up to ~80 base pairs). It achieves this through a fundamentally different mechanism.

The Molecular Machine: Three Components

The prime editor is a fusion protein with three key elements:

1. Cas9 nickase (nCas9): A modified version of Cas9 where one of two cutting domains has been disabled. Instead of cutting both DNA strands, it "nicks" — cuts — only one strand. This is the critical safety feature: no double-strand break.

2. Reverse transcriptase (RT): An engineered enzyme fused to the Cas9 nickase. Reverse transcriptase reads an RNA template and writes a corresponding DNA strand — the reverse of normal transcription. The version used in prime editing is an engineered M-MLV reverse transcriptase with five mutations that optimize its performance at body temperature.

3. Prime editing guide RNA (pegRNA): This is the most innovative component. A pegRNA is a single RNA molecule that serves double duty. Its front end (the spacer) guides the editor to the correct location in the genome, just like a standard CRISPR guide RNA. Its back end carries the reverse transcriptase template (RTT) — a stretch of RNA that encodes the desired edit — and a primer binding site (PBS) that anchors the editor to the nicked DNA strand.

The pegRNA literally carries the corrected genetic information to the target site. The reverse transcriptase reads the template and writes the correction directly into the DNA.

The Evolution: PE1 Through PE7

Prime editing has improved rapidly since its initial publication:

• PE1 (2019): The original system. Proof of concept, but editing efficiency was modest — typically 0.7-5.5% in human cells.
• PE2 (2019): An engineered reverse transcriptase with improved thermostability and processivity. Editing efficiency jumped 1.6-5.1-fold over PE1.
• PE3 (2019): Added a secondary nicking guide RNA that nicks the non-edited strand, biasing the cell's mismatch repair machinery to use the edited strand as the template. Efficiency increased another 1.5-4.2-fold, reaching up to 33% in some targets.
• PE4 and PE5 (2022): Incorporated a transient mismatch repair inhibitor (dominant-negative MLH1), pushing efficiency to 50-70% in many targets.
• PE6 (2023): A smaller, split-intein version of the prime editor that fits into adeno-associated virus (AAV) vectors for in vivo delivery — a critical advance for reaching tissues inside the body.
• PE7 (2024): Incorporated an RNA-binding protein (La protein) to stabilize the pegRNA against cellular degradation. This increased editing efficiency another 2-7-fold across diverse cell types, consistently exceeding 80% in some contexts.

Each generation brought prime editing closer to clinical viability. PM359, the therapy used in the first patient, employed a proprietary prime editing system optimized for human hematopoietic stem cells.

The First Patient: Chronic Granulomatous Disease

What Is CGD?

Chronic granulomatous disease is a rare inherited immune disorder affecting approximately 1 in 200,000 to 1 in 250,000 people. It is caused by mutations in genes encoding subunits of the NADPH oxidase complex, an enzyme system that neutrophils and other phagocytes use to generate reactive oxygen species — the chemical weapons these immune cells deploy to kill bacteria and fungi after engulfing them.

In CGD, neutrophils can still find and swallow pathogens, but they cannot kill them. The bacteria and fungi survive inside the immune cells and establish chronic infections, particularly in the lungs, liver, lymph nodes, and skin. Patients suffer from recurrent, life-threatening infections and the formation of granulomas — clusters of immune cells that accumulate at sites of persistent infection but fail to clear it.

The most common form, X-linked CGD, accounts for about 65% of cases and is caused by mutations in the CYBB gene (also known as gp91phox or NOX2), located on the X chromosome. This means it predominantly affects males. Without treatment, many patients die in childhood or young adulthood from overwhelming infections. Current management relies on lifelong prophylactic antibiotics and antifungals, with bone marrow transplant from a matched donor as the only curative option — a procedure that carries significant risks, including graft-versus-host disease and transplant-related mortality.

Why Prime Medicine Chose CGD

CGD was a strategically astute first target for several reasons:

Single gene, known mutation: X-linked CGD is caused by well-characterized mutations in a single gene (CYBB). A defined molecular target is essential for a precision editing approach.

Clear functional readout: NADPH oxidase activity can be measured directly using a dihydrorhodamine (DHR) flow cytometry assay. If the edit works, corrected neutrophils will produce reactive oxygen species, and you can count exactly what percentage of cells are functional. This gives investigators an unambiguous, quantitative measure of success within weeks of treatment — far faster than waiting months or years for clinical endpoints.

Low correction threshold: Studies of CGD carriers (women with one normal and one mutated copy of CYBB) and patients who have undergone allogeneic bone marrow transplant show that restoring NADPH oxidase activity in as few as 10-20% of neutrophils is sufficient to provide meaningful clinical protection against infections. This meant the therapy did not need to correct every cell — a realistic bar for a first-in-human study.

Ex vivo delivery: The treatment could be performed ex vivo — removing the patient's own hematopoietic stem cells, editing them in the laboratory, and infusing them back. This avoids the immense challenge of in vivo delivery (getting the editor to the right cells inside the body) and allows quality control of the edited cells before reinfusion.

Unmet medical need: For patients without a matched bone marrow donor, there was no curative option. Previous gene therapy attempts for CGD using viral vectors (gamma-retroviruses and lentiviruses) had shown some promise but were plagued by inconsistent results, silencing of the therapeutic gene, and, in early trials, insertional oncogenesis — the activation of cancer-causing genes by the viral vector inserting in the wrong place.

PM359: The Therapy

PM359 is an ex vivo autologous cell therapy. The process works as follows:

1. Stem cell collection: Hematopoietic stem and progenitor cells (HSPCs) are mobilized from the patient's bone marrow into the peripheral blood using granulocyte colony-stimulating factor (G-CSF) and plerixafor, then collected via apheresis.

2. Prime editing: The harvested CD34+ HSPCs are electroporated with the prime editing components — the prime editor protein (or mRNA encoding it) and the pegRNA targeting the specific CYBB mutation. The editor finds the mutant sequence and rewrites it to the normal sequence.

3. Quality control: Edited cells are analyzed to confirm on-target editing efficiency, verify low off-target editing, and ensure the cells retain their ability to engraft (take up residence in the bone marrow and produce blood cells long-term).

4. Conditioning and infusion: The patient receives myeloablative conditioning (chemotherapy to make room in the bone marrow), followed by infusion of the corrected cells.

The critical advantage of prime editing over previous approaches: it corrects the patient's own gene in its natural chromosomal context, under its native regulatory elements. There is no randomly inserted transgene to be silenced, no viral vector to cause insertional mutagenesis.

The Moment of Truth: May 2025

The first patient received their infusion of PM359-corrected cells in May 2025, under a Phase 1/2 clinical trial (PM-CGD-101). The medical team then waited — monitoring blood counts for engraftment, and critically, measuring NADPH oxidase activity in circulating neutrophils using the DHR assay.

The Results That Exceeded Expectations

The Numbers

The results, first presented at the American Society of Hematology (ASH) annual meeting in December 2025 and subsequently published in the New England Journal of Medicine, told a remarkable story:

• Day 15 post-infusion: NADPH oxidase activity was detected in 58% of circulating neutrophils. At two weeks, more than half the patient's neutrophils were already producing the reactive oxygen species that their immune system had never been able to generate.

• Day 30 post-infusion: The proportion rose to 66%. Two-thirds of neutrophils were now functionally corrected.

• Safety: No serious adverse events attributable to the prime editing component were reported. The side effects observed — mucositis, neutropenic fever — were consistent with the myeloablative conditioning regimen, not the edited cells themselves.

What These Numbers Mean

To appreciate the significance, consider the context:

The clinical benefit threshold was 20%. Based on decades of data from CGD carriers and transplant recipients, the field had established that correcting approximately 10-20% of neutrophils provides clinically meaningful protection against the severe infections that define CGD. PM359 achieved more than three times that threshold in a single patient at the one-month mark.

Previous gene therapy attempts for CGD fell short. In earlier clinical trials using lentiviral vectors to deliver a functional copy of CYBB, sustained correction rates were inconsistent. A 2021 trial of a lentiviral gene therapy achieved a median of approximately 16% oxidase-positive neutrophils at 12 months. Some patients lost correction over time as the transgene was silenced. PM359 achieved 66% correction at one month — though longer follow-up will be needed to assess durability.

Comparison to other gene editing therapies: The approved CRISPR-Cas9 therapy Casgevy (exagamglogene autotemcel), which treats sickle cell disease and beta-thalassemia by reactivating fetal hemoglobin, achieves its effect through gene disruption rather than correction. The editing efficiency in the infusion product is typically greater than 80%, but the biological mechanism is fundamentally different — Casgevy does not fix the disease-causing mutation. PM359 actually corrects the defective gene to its normal sequence.

For prime editing specifically, these results were transformative. Before this trial, the question was whether prime editing — which is more complex and generally less efficient than simpler CRISPR-Cas9 disruption — could achieve therapeutically relevant editing levels in a true clinical setting. The answer was unequivocally yes.

Caveats and Open Questions

Scientific honesty requires noting what we do not yet know:

• This is a single patient. The results are striking, but n=1 is not sufficient to draw definitive conclusions about efficacy or safety. More patients, longer follow-up, and controlled comparisons are needed.

• Durability is unproven. The one-month data are encouraging, but hematopoietic stem cell therapies can show initial correction rates that decline over time if the edited long-term repopulating stem cells do not engraft as efficiently as the shorter-lived progenitor cells. The field will be watching 6-month and 12-month data closely.

• Off-target editing. While no off-target concerns were flagged in pre-clinical or early clinical data, comprehensive genome-wide off-target analysis in the treated patient's cells will take time to complete and publish.

• Conditioning toxicity. The patient required myeloablative chemotherapy — a toxic process that carries its own risks. Developing less toxic conditioning regimens is an active area of research across the entire field of ex vivo gene therapy.

Why Prime Medicine Pivoted Away from CGD

Here is where the story takes an unexpected turn. Despite producing arguably the most impressive first-in-human data for any gene editing therapy to date, Prime Medicine announced in early 2026 that it would wind down its CGD program. No additional patients would be enrolled.

This was not a failure of science. It was a strategic business decision — and understanding it illuminates the often uncomfortable tension between scientific achievement and commercial viability.

The Ultra-Rare Disease Problem

CGD affects approximately 1 in 200,000 to 1 in 250,000 people. In the United States, that translates to roughly 1,000-1,500 patients total. X-linked CGD — the specific form targeted by PM359 — accounts for about 65% of cases, narrowing the addressable population further. And not all of those patients will be candidates for an ex vivo cell therapy requiring myeloablative conditioning.

The commercial reality is stark: even at the high price points typical of gene therapies ($1-3 million per treatment), the total addressable market for a CGD prime editing therapy is small. The cost of running a full Phase 3 trial, building manufacturing capacity, seeking regulatory approval, and maintaining post-market surveillance could easily exceed the lifetime revenue from the therapy.

This is the same economic calculus that has slowed or killed other promising rare disease therapies. The science works, but the business case does not.

The Strategic Pivot to Larger Indications

In late 2025 and early 2026, Prime Medicine announced a strategic refocusing toward liver and lung diseases — indications with significantly larger patient populations.

Wilson's Disease (PM577a)

Wilson's disease is a genetic disorder caused by mutations in the ATP7B gene, which encodes a copper-transporting ATPase in the liver. Without functional ATP7B, copper accumulates in the liver, brain, and other organs, causing liver disease, neurological symptoms, and psychiatric disturbances. It affects approximately 1 in 30,000 people worldwide — still rare, but an order of magnitude more common than CGD.

Prime Medicine's program, PM577a, uses in vivo delivery of a prime editor to correct ATP7B mutations directly in hepatocytes (liver cells). This is a more technically challenging approach than the ex vivo strategy used for CGD, because the editor must be delivered to the target organ inside the body — but liver-directed gene therapies have a strong track record, with lipid nanoparticles (LNPs) and AAV vectors both capable of efficient hepatocyte delivery.

The Investigational New Drug (IND) filing for PM577a is on track for the first half of 2026, which would make it Prime Medicine's next clinical program.

Alpha-1 Antitrypsin Deficiency (AATD)

Alpha-1 antitrypsin deficiency is caused by mutations in the SERPINA1 gene, most commonly the Z mutation (Glu342Lys). This single amino acid change causes the AAT protein to misfold and polymerize in hepatocytes, leading to liver disease, while the resulting deficiency of functional AAT in the lungs leads to early-onset emphysema. AATD affects an estimated 1 in 2,500 to 1 in 5,000 people of European descent — a vastly larger patient population than CGD.

AATD is a particularly compelling target for prime editing because the disease is caused by a single, well-characterized point mutation. Correcting the Z mutation would address both the liver disease (by stopping toxic protein accumulation) and the lung disease (by restoring normal AAT secretion). Clinical trials for this indication are expected to begin in 2026.

Business Reality vs. Scientific Triumph

Prime Medicine's CGD pivot is not unique. The gene therapy field has repeatedly seen scientifically successful rare disease programs fail commercially. Bluebird Bio's Skysona for cerebral adrenoleukodystrophy was pulled from the European market in 2022 over pricing disputes. The lesson is consistent: in the current healthcare economic environment, breakthrough science for very small patient populations often cannot sustain the companies that develop it.

The CGD data accomplished their purpose: they proved that prime editing works in humans. That proof of concept is now the foundation for Prime Medicine's entire pipeline. The CGD patient's neutrophils, producing reactive oxygen species at rates that exceeded every reasonable benchmark, are the strongest possible argument for prime editing's therapeutic potential — even if the therapy that generated those results will never become a marketed product.

Prime Editing vs. Other Approaches

Understanding where prime editing fits in the gene editing toolkit requires comparing it directly to alternative technologies.

Comparison Table

Feature	CRISPR-Cas9	Base Editing	Prime Editing	Epigenetic Editing
Mechanism	Double-strand break	Chemical base conversion	Reverse transcription from pegRNA	Chromatin modification
DSBs?	Yes	No	No	No
Edit types	Disruption, HDR-mediated correction	4 of 12 point mutations (C-to-T, A-to-G)	All 12 point mutations + small indels	Gene silencing or activation
Off-target profile	Indels at off-target DSBs	Bystander edits in editing window; RNA off-targets (CBEs)	Low off-target indels; minimal bystander editing	Potential spread of chromatin marks
Efficiency	High for disruption; low for precise HDR	High (often 40-80%)	Moderate to high (5-80%, generation-dependent)	High for silencing
Size of editor	~4.1 kb (SpCas9)	~5.2 kb (ABE8e)	~6.3 kb (PE2)	Variable (~4-6 kb)
Delivery challenge	Moderate	Moderate-high	High (largest editor)	Moderate
Best suited for	Gene knockout, large deletions	Correcting C/T or A/G transitions	Versatile correction of any small mutation	Reversible gene regulation

When Prime Editing Is the Best Choice

Prime editing is the clear winner when:

• The disease-causing mutation requires a transversion (e.g., T-to-A, G-to-C) that base editors cannot make. Of the roughly 75,000 known pathogenic point mutations in ClinVar, only about one-third are addressable by current base editors. Prime editing can theoretically correct nearly all of them.

• The correction requires a small insertion or deletion — for example, restoring a deleted codon or removing an aberrant splice site.

• Precision is paramount — when bystander edits at neighboring bases would be harmful, or when the target site has multiple bases of the same type in the editing window.

• Avoiding double-strand breaks is essential — in clinical settings where the risk of chromosomal rearrangements or p53-mediated toxicity from DSBs is unacceptable.

Current Limitations

Prime editing is not without significant challenges:

• Editor size: At approximately 6.3 kilobases for the protein-coding sequence alone, the prime editor is too large for standard single-AAV delivery. This has driven the development of split-intein approaches (PE6) and alternative delivery methods like LNPs and engineered virus-like particles (eVLPs).

• Efficiency variation: Editing efficiency varies substantially depending on the target sequence, pegRNA design, cell type, and chromatin context. Some targets edit at greater than 80%, others at less than 10%. Computational tools for pegRNA design have improved, but this remains a significant practical challenge.

• Manufacturing complexity: For ex vivo therapies, the manufacturing process — electroporation of stem cells with prime editing components, quality control, conditioning, and infusion — is complex and expensive. Each treatment is custom-manufactured for a single patient.

• Delivery for in vivo applications: Getting the large prime editing machinery into target cells inside a living patient is the field's biggest technical hurdle. LNP delivery to the liver is relatively mature, but reaching other organs (brain, muscle, lung epithelium) remains difficult.

What's Next for Prime Editing Therapeutics

The Prime Medicine Pipeline

Beyond CGD, Wilson's disease, and AATD, Prime Medicine has disclosed several additional programs:

• Prion diseases: Preclinical work on disrupting the PRNP gene to prevent or treat fatal familial insomnia and Creutzfeldt-Jakob disease.
• Liver-directed programs: A broader platform for hepatic metabolic diseases, leveraging LNP delivery.
• Partnerships: Collaborations with academic medical centers for additional rare disease applications.

Other Players in the Prime Editing Space

Prime Medicine is not the only company investing in prime editing:

• Beam Therapeutics (founded by David Liu, along with base editing pioneers Feng Zhang and J. Keith Joung) has disclosed prime editing capabilities alongside its base editing programs. While Beam's lead clinical programs use base editing, the company holds foundational IP in prime editing.

• The Broad Institute continues to advance prime editing research, including twin prime editing (which uses two pegRNAs to enable large-scale insertions and genomic rearrangements) and the PASTE system (which combines prime editing with site-specific recombinases to insert large DNA payloads of up to 36 kilobases).

• Academic groups worldwide are actively applying prime editing to disease models for sickle cell disease (HBB E6V correction), cystic fibrosis (CFTR deltaF508 correction), Tay-Sachs disease, and dozens of other monogenic conditions.

• Delivery-focused companies like Intellia Therapeutics and Verve Therapeutics, while currently using Cas9-based approaches, are closely monitoring prime editing advances and could adopt the technology as delivery platforms mature.

Key Technical Challenges Remaining

Several technical hurdles must be cleared before prime editing can achieve its full therapeutic potential:

1. In vivo delivery beyond the liver: LNPs work well for hepatocytes, but efficiently delivering the large prime editing machinery to the lungs, brain, heart, or skeletal muscle is an unsolved problem. Engineered AAVs, eVLPs, and next-generation LNPs are all being pursued.

2. Efficiency optimization: While PE7 represents a major advance, consistently achieving greater than 50% editing in therapeutically relevant cell types in vivo remains challenging. Continued protein engineering and pegRNA design improvements will be critical.

3. Immunogenicity: The prime editor contains bacterial (Cas9) and viral (reverse transcriptase) protein components that the human immune system may recognize as foreign. For ex vivo therapies, the editor is not present in the final cell product, but for in vivo delivery, immune responses could limit efficacy or cause toxicity — especially with repeat dosing.

4. Manufacturing scale and cost: Autologous ex vivo cell therapies are inherently expensive because each treatment is manufactured individually. Developing allogeneic ("off-the-shelf") approaches using donor cells edited with prime editing could dramatically reduce costs, but introduces additional challenges including immune rejection.

5. Regulatory pathways: Prime editing is sufficiently novel that regulatory agencies are still developing frameworks for evaluating its safety. The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is actively working on guidance specific to gene editing therapies that make precise corrections (as opposed to gene disruption or addition).

Potential Disease Targets on the Horizon

The versatility of prime editing opens an enormous range of potential applications:

• Sickle cell disease: Direct correction of the HBB E6V mutation, rather than the indirect approach (fetal hemoglobin reactivation) used by Casgevy. This could provide a more physiologically complete cure.

• Cystic fibrosis: Correction of the CFTR deltaF508 mutation directly in lung epithelial cells — if in vivo lung delivery can be solved.

• Phenylketonuria (PKU): Correction of PAH mutations in hepatocytes to restore phenylalanine metabolism.

• Hereditary tyrosinemia type 1: Liver-directed correction of FAH mutations.

• Duchenne muscular dystrophy: While the gene (DMD) is enormous, prime editing could correct specific exon-skipping mutations — though muscle delivery remains a challenge.

• Neurological diseases: With the development of effective CNS delivery, conditions like Huntington's disease, spinal muscular atrophy, and certain forms of epilepsy could become addressable.

Timeline Expectations

For observers tracking the field, a realistic timeline looks something like this:

• 2026: IND filing for PM577a (Wilson's disease). Potential IND for AATD. Continued follow-up data from the CGD patient.
• 2026-2027: First in vivo prime editing clinical trials (liver-directed).
• 2027-2028: Emergence of next-generation delivery platforms enabling prime editing in non-liver tissues.
• 2028-2030: Potential for first regulatory approvals if clinical data support it.

These timelines are inherently uncertain. Gene therapy development has a history of moving more slowly than initial optimism suggests. But the CGD proof-of-concept data provide a stronger foundation for confidence than the field has ever had before.

Frequently Asked Questions

What is prime editing and how does it work?

Prime editing is a gene editing technology that can find a specific DNA sequence and rewrite it without cutting both strands of the DNA helix. It uses three components: a Cas9 nickase that cuts only one strand, a reverse transcriptase enzyme that writes new DNA from an RNA template, and a prime editing guide RNA (pegRNA) that both directs the editor to the target site and carries the corrected genetic information. Think of it as a biological "find-and-replace" function.

Has prime editing been tested in humans and what were the results?

Yes. In May 2025, Prime Medicine dosed the first patient with PM359 for chronic granulomatous disease (CGD) in the PM-CGD-101 trial. By day 15, NADPH oxidase activity was detected in 58% of circulating neutrophils, rising to 66% by day 30 — more than three times the 20% clinical benefit threshold. No serious adverse events attributable to the prime editing component were reported.

Why did Prime Medicine stop its CGD program despite great results?

Prime Medicine wound down the CGD program for commercial, not scientific, reasons. CGD affects approximately 1 in 200,000-250,000 people, translating to roughly 1,000-1,500 total U.S. patients, with the X-linked form narrowing the addressable population further. The cost of running a full Phase 3 trial, building manufacturing capacity, and maintaining post-market surveillance could easily exceed the lifetime revenue from such a small market.

What diseases can prime editing treat?

Prime editing can theoretically correct nearly all of the roughly 75,000 known pathogenic point mutations in ClinVar — far more than base editing, which addresses only about one-third. Prime Medicine is now focused on Wilson's disease (PM577a, IND filing expected H1 2026) and alpha-1 antitrypsin deficiency (AATD), which affects 1 in 2,500-5,000 people. Other potential targets include sickle cell disease, cystic fibrosis, PKU, and Duchenne muscular dystrophy.

How does prime editing compare to CRISPR-Cas9 and base editing?

Prime editing makes no double-strand break (unlike Cas9) and can perform all 12 types of point mutations plus small insertions and deletions (unlike base editors, which can only make 4 of 12 single-letter changes). Its main limitations are larger editor size (~6.3 kb, making AAV delivery challenging) and variable efficiency depending on target sequence and cell type, though the latest generation (PE7) consistently exceeds 80% efficiency in some contexts.

The Bottom Line

The first human results for prime editing therapy — 66% neutrophil correction in a CGD patient against a 20% clinical benefit threshold — represent a watershed moment for genetic medicine. They prove that the most versatile gene editing tool ever created can work safely and effectively in a patient. While Prime Medicine's pivot away from CGD underscores the brutal economics of ultra-rare diseases, the scientific validation is permanent: prime editing has arrived in the clinic, and the question is no longer whether it works in humans, but how broadly it can be applied.

Sources & Further Reading

• Anzalone, A.V., Randolph, P.B., Davis, J.R., et al. "Search-and-replace genome editing without double-strand breaks or donor DNA." Nature 576, 149-157 (2019). https://doi.org/10.1038/s41586-019-1711-4

• Chen, P.J., Hussmann, J.A., Yan, J., et al. "Enhanced prime editing systems by manipulating cellular determinants of editing outcomes." Cell 184, 5635-5652 (2021). https://doi.org/10.1016/j.cell.2021.09.018

• Davis, J.R., Banskota, S., Levy, J.M., et al. "Efficient prime editing in mouse brain, liver and heart with dual AAVs." Nature Biotechnology 42, 253-264 (2024). https://doi.org/10.1038/s41587-023-01758-z

• Prime Medicine. "Prime Medicine Announces First Patient Dosed in Phase 1/2 Clinical Trial of PM359 for Chronic Granulomatous Disease." Press release, May 2025. https://www.primemedicine.com/news/

• Prime Medicine. "Prime Medicine Reports Positive Initial Clinical Data from PM-CGD-101 Trial." Presentation at ASH Annual Meeting, December 2025. https://www.primemedicine.com/pipeline/

• Kohn, D.B., Booth, C., Shaw, K.L., et al. "Autologous ex vivo lentiviral gene therapy for chronic granulomatous disease." Nature Medicine 26, 27-38 (2020). https://doi.org/10.1038/s41591-019-0735-5

• Newby, G.A. & Liu, D.R. "In vivo somatic cell base editing and prime editing." Molecular Therapy 29, 3107-3124 (2021). https://doi.org/10.1016/j.ymthe.2021.09.002

• National Institutes of Health. "Chronic Granulomatous Disease." Genetics Home Reference. https://medlineplus.gov/genetics/condition/chronic-granulomatous-disease/

• ClinicalTrials.gov. Search: "Prime Medicine" or "prime editing." https://clinicaltrials.gov/

• Doudna, J.A. & Charpentier, E. "The new frontier of genome engineering with CRISPR-Cas9." Science 346, 1258096 (2014). https://doi.org/10.1126/science.1258096